U.S. Department of Health & Human Services
National Institutes of Health
NCATS
Return Home
Inxight
Drugs
Search Substances
Home
Browse Drugs
US Approved Drugs
Marketed Drugs
Investigational Drugs
All Substances
Search
Structure Search
Sequence Search
Downloads
About
Search Substances
CATUMAXOMAB
M2HPV837HO
Possibly Marketed Outside US
General
Record Details
Names
6
Classification
7
Identifiers
12
Relationships
6
Active Moiety
1
Characteristic Attributes
2
CATUMAXOMAB
M2HPV837HO
Possibly Marketed Outside US
General
Approval Year
Unknown
139,594
Record Details
Substance Class
Protein
Protein Type
MONOCLONAL ANTIBODY
Protein Sub Type
IGG2A
Sequence Origin
RAT-MOUSE HYBRID
Sequence Type
UNKNOWN
Record UNII
M2HPV837HO
Record Status
Validated (UNII)
Record Version
18
17
16
15
14
13
12
11
10
9
8
7
6
5
4
3
2
1
Names
6
Show
5
20
100
All
entries
Name
Type
Language
Name
Type
Language
CATUMAXOMAB
Official Name
English
catumaxomab [INN]
Common Name
English
REMOVAB
Brand Name
English
CATUMAXOMAB [MI]
Common Name
English
RAT-MOUSE HYBRID MONOCLONAL ANTIBODY TO CD3 AND EPCAM
Common Name
English
Showing 1 to 5 of 6 entries
Previous
1
2
Next
Classification
7
Show
5
20
100
All
entries
Classification Tree
Code System
Code
Classification Tree
Code System
Code
Designated
ORPHAN DRUG
Designated
Treatment of gastric cancer
FDA ORPHAN DRUG
284509
PATHOLOGIC PROCESSES
EMA EPAR
DISEASES
SYMPTOMS AND GENERAL PATHOLOGY
PATHOLOGIC PROCESSES
ASCITES
EMA ASSESSMENT REPORTS
REMOVAB (AUTHORIZED: ASCITES)
Monoclonal antibodies
VATC
ANTINEOPLASTIC AGENTS
OTHER ANTINEOPLASTIC AGENTS
Monoclonal antibodies
catumaxomab
WHO-VATC
QL01XC09
Biological Agent
Pharmacologic Substance
[C1909]
Biological Agent
[C307]
Bispecific Antibody
NCI_THESAURUS
C1454
Monoclonal antibodies
ATC
ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS
ANTINEOPLASTIC AGENTS
OTHER ANTINEOPLASTIC AGENTS
Monoclonal antibodies
catumaxomab
WHO-ATC
L01XC09
Showing 1 to 5 of 7 entries
Previous
1
2
Next
Identifiers
12
Show
5
20
100
All
entries
Code System
Code
Type
Description
Code System
Code
Type
Description
CAS
509077-98-9
PRIMARY
DRUG BANK
DB06607
PRIMARY
INN
8406
PRIMARY
MESH
C522419
PRIMARY
NCI_THESAURUS
C62445
PRIMARY
Showing 1 to 5 of 12 entries
Previous
1
2
3
Next
Relationships
6
Show
5
20
100
All
entries
Related Record
Type
Details
Related Record
Type
Details
ZLW14X2D30
CD3
TARGET -> ACTIVATOR
NN8BA411GP
LOW AFFINITY IMMUNOGLOBULIN GAMMA FC REGION RECEPTOR III-A
TARGET -> AGONIST
Amount:
JA0XKI4FW7
HIGH AFFINITY IMMUNOGLOBULIN GAMMA FC RECEPTOR I
TARGET -> AGONIST
1U72JD9DDZ
T-CELL SURFACE GLYCOPROTEIN CD3 EPSILON CHAIN
TARGET -> ACTIVATOR
ZLW14X2D30
CD3
TARGET -> INHIBITOR
Showing 1 to 5 of 6 entries
Previous
1
2
Next
Active Moiety
1
Show
5
20
100
All
entries
Related Record
Type
Details
Related Record
Type
Details
M2HPV837HO
CATUMAXOMAB
ACTIVE MOIETY
Showing 1 to 1 of 1 entries
Previous
1
Next
Characteristic Attributes
2
Show
5
20
100
All
entries
Name
Property Type
Amount
Referenced Substance
Defining
Parameters
References
Name
Property Type
Amount
Referenced Substance
Defining
Parameters
References
Molecular Formula
CHEMICAL
ESTIMATED
MOL_WEIGHT:ESTIMATE
CHEMICAL
ESTIMATE 147000 AMU (average)
Showing 1 to 2 of 2 entries
Previous
1
Next
